Growing International Pharmaceutical Company Awards $1 Million Study to eResearchTechnology for Cardiac Safety Monitoring and In
June 22 2004 - 9:05AM
PR Newswire (US)
Growing International Pharmaceutical Company Awards $1 Million
Study to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Award Addresses Significant Late
Phase Study for Key Clinical Development Program PHILADELPHIA, June
22 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT),
(NASDAQ:ERES), a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has been awarded approximately $1 million
in cardiac safety monitoring and services from a growing
international pharmaceutical organization for one of its key drug
candidates in later phase clinical trials. The award covers an
extensive Phase III study, for which eRT will provide comprehensive
support, including provision of 180 units of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data
that is subsequently provided to eRT for analysis. eRT will perform
digital collection, measurement, interpretation, review, and
distribution of cardiac safety data through its EXPeRT(R) workflow
enabled data handling technology, the first solution in production
that was designed explicitly to meet emerging international
regulatory guidance and technical standards. "We are pleased that
eRT has been selected by the sponsor to provide cardiac safety
services for this critical late phase study on an important
compound," said Scott Grisanti, senior vice president of business
development and chief marketing officer at eRT. "eRT's ability to
marshal and support large volumes of digital ECG collection
equipment for supply to investigative sites was key to this
initiative, which is indicative of the extensive cardiac safety
profiling being incorporated into late phase development programs
in response to emerging regulations and global standards." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The sponsor
may cancel this agreement at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Reports on Forms 10-K and 10-Q filed with the Securities
and Exchange Commission. DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, Inc.,
+1-908-203-6473; or Matt Hayden of Hayden Communications,
+1-858-456-4533, for eResearchTechnology, Inc. Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles